{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:52:10Z","timestamp":1791096730830,"version":"4.1.0"},"reference-count":44,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2012,1,12]],"date-time":"2012-01-12T00:00:00Z","timestamp":1326326400000},"content-version":"vor","delay-in-days":1137,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:p><jats:bold>Study Objective.<\/jats:bold> To investigate the potential effect of atorvastatin 80 mg\/day on the pharmacokinetics and pharmacodynamics of the thienopyridines prasugrel and clopidogrel.<\/jats:p><jats:p><jats:bold>Design.<\/jats:bold> Open\u2010label, randomized, crossover, two\u2010arm, parallel\u2010group study.<\/jats:p><jats:p><jats:bold>Setting.<\/jats:bold> Single clinical research center in the United Kingdom.<\/jats:p><jats:p><jats:bold>Participants.<\/jats:bold> Sixty\u2010nine healthy men aged 18\u201360 years.<\/jats:p><jats:p><jats:bold>Intervention.<\/jats:bold> Subjects received either a loading dose of prasugrel 60 mg followed by a maintenance dose of 10 mg\/day or a loading dose of clopidogrel 300 mg followed by 75 mg\/day. The drug was given as monotherapy for 10 days, and after a 6\u2010day run\u2010in period with atorvastatin 80 mg\/day, the same dosage of atorvastatin was continued with the respective thienopyridine for 10 days. A 14\u2010day washout period separated the treatment regimens.<\/jats:p><jats:p><jats:bold>Measurements and Main Results.<\/jats:bold> Blood samples were collected before and at various time points after dosing on days 1 and 11 for determination of plasma concentrations of metabolites and for measurement of platelet aggregation induced by adenosine 5\u2032\u2010diphosphate 20 \u03bcM and vasodilator\u2010stimulated phosphoprotein (VASP). Coadministration of atorvastatin did not alter exposure to active metabolites of prasugrel or clopidogrel after the loading dose and thus did not alter inhibition of platelet aggregation (IPA). During maintenance dosing, atorvastatin administration resulted in 17% and 28% increases in the area under the plasma concentration\u2010time curve (AUC) values of prasugrel's and clopidogrel's active metabolites, respectively. These small changes in AUC did not result in a significant change in IPA response to prasugrel but did result in a significant increase in IPA during clopidogrel maintenance dosing at some, but not all, of the time points on day 11. Coadministration of atorvastatin with either prasugrel or clopidogrel had no effect on VASP phosphorylation relative to the thienopyridine alone after the loading dose.<\/jats:p><jats:p><jats:bold>Conclusion.<\/jats:bold> Coadministration of atorvastatin 80 mg\/day with prasugrel or clopidogrel did not negatively affect the antiplatelet response to either drug after a loading dose or during maintenance dosing. The lack of a clinically meaningful effect of high\u2010dose atorvastatin on the pharmacodynamic response to prasugrel after the loading or maintenance dose indicates that no dosage adjustment should be necessary in patients receiving these drugs concomitantly.<\/jats:p>","DOI":"10.1592\/phco.28.12.1483","type":"journal-article","created":{"date-parts":[[2008,11,24]],"date-time":"2008-11-24T08:04:42Z","timestamp":1227513882000},"page":"1483-1493","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects"],"prefix":"10.1002","volume":"28","author":[{"given":"Nagy A.","family":"Farid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Jakubowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying G.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"C. Steven","family":"Ernest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Konkoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Winters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,12]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161206776361318"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3027"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703237"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000037106.76139.53"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.2007.00027.x"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi877"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02792.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.10.010"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e3181492209"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.02.103"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.020248"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.007989"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.014522"},{"issue":"2","key":"e_1_2_1_15_2","first-page":"99","article-title":"In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in the active metabolite formation [abstract]","volume":"37","author":"Kurihara A","year":"2005","journal-title":"Drug Metab Rev"},{"key":"e_1_2_1_16_2","first-page":"918","volume-title":"Physicians' desk reference. Plavix (clopidogrel) package insert","year":"2007"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.110577"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.1.53"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100139"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000047060.60595.CC"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-668X(03)00442-1"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000099507.32936.C0"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000124581.18191.15"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/0953710412331272532"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2004.035014"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000088780.57432.43"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2003.10.039"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.18.2051"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi139"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.01.097"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.08.036"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.2813"},{"issue":"1","key":"e_1_2_1_33_2","article-title":"Stabilization of the clopidogrel active metabolite in whole blood and its assay in human plasma by LCMS\/MS [abstract]","author":"Takahashi M","year":"2006","journal-title":"J Am Soc Mass Spectrom"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1985.tb07467.x"},{"key":"e_1_2_1_35_2","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1055\/s-0037-1615584","article-title":"High stability of blood samples for flow cytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease","volume":"94","author":"Aleil B","year":"2005","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_36_2","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation and Research.Guidance for industry: in vivo drug metabolism\/drug interaction studies\u2014study design data analysis and recommendations for dosing and labeling. Available fromhttp:www.fda.govcderguidance2635fnl.htm. Accessed May 11 2007."},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.7.815"},{"issue":"1","key":"e_1_2_1_38_2","first-page":"125","article-title":"Effect of induction by rifampicin on the pharmacokinetics of prasugrel metabolites in healthy subjects [abstract]","volume":"39","author":"Farid NA","year":"2007","journal-title":"Drug Metab Rev"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02598.x"},{"issue":"1","key":"e_1_2_1_40_2","first-page":"S200","article-title":"Prasugrel 60 mg and clopidogrel 300 mg loading doses: a pharmacokinetic basis for the observed difference in platelet aggregation response [abstract]","volume":"98","author":"Small DS","year":"2006","journal-title":"Am J Cardiol"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn212"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(03)00626-X"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.5.488"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.008672"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20784"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.28.12.1483","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.28.12.1483","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:32:17Z","timestamp":1761060737000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.28.12.1483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["10.1592\/phco.28.12.1483"],"URL":"https:\/\/doi.org\/10.1592\/phco.28.12.1483","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12]]},"assertion":[{"value":"2012-01-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}